These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 19802972

  • 1. In-vitro studies with ceftazidime.
    Giamarellou H, Avlami A, Matsakas V, Kosmidis J, Daikos GK.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():73-7. PubMed ID: 19802972
    [Abstract] [Full Text] [Related]

  • 2. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G, Johnston J, Young LS, Martin WJ.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [Abstract] [Full Text] [Related]

  • 3. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA.
    Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
    [Abstract] [Full Text] [Related]

  • 4. Antibacterial activity of ceftazidime (GR 20263) against routine hospital isolates and highly resistant strains of enterobacteriaceae and Pseudomonas aeruginosa.
    Leigh DA, Nisbet D.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():107-10. PubMed ID: 19802975
    [Abstract] [Full Text] [Related]

  • 5. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 6. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime].
    Rouhan D, Le Noc P, Le Noc D.
    Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713
    [Abstract] [Full Text] [Related]

  • 7. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I, Warren C, Shannon K, King A, Hanslo D.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activity of ceftazidime compared with other beta-lactam antibiotics.
    Clarke AM, Zemcov SJ.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():57-62. PubMed ID: 19810169
    [Abstract] [Full Text] [Related]

  • 10. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM, Guenthner SH, Wenzel RP.
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [Abstract] [Full Text] [Related]

  • 11. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A, Meyran M, Huerre M.
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [Abstract] [Full Text] [Related]

  • 12. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
    Neu HC.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
    [Abstract] [Full Text] [Related]

  • 13. The in-vitro properties of ceftazidime.
    Harper PB.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():5-13. PubMed ID: 19802965
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
    Shibl AM, Ishag AH, Durgham SM.
    Chemotherapy; 1989 Sep; 35 Suppl 1():72-6. PubMed ID: 2659292
    [Abstract] [Full Text] [Related]

  • 15. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
    Wilkinson LD, Gentry LO.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL, Jacobus NV, Tally FP, Gorbach SL.
    Clin Ther; 1983 Sep; 5(6):603-16. PubMed ID: 6313195
    [Abstract] [Full Text] [Related]

  • 17. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P, Ryan DM, Sowa MA, Watts CM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [Abstract] [Full Text] [Related]

  • 18. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L, Dornbusch K, Hallander HO.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [Abstract] [Full Text] [Related]

  • 19. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ, Wang H, China Nosocomial Pathogens Resistance Surveillance Study Group.
    Zhonghua Yi Xue Za Zhi; 2003 Mar 10; 83(5):375-81. PubMed ID: 12820912
    [Abstract] [Full Text] [Related]

  • 20. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN.
    Int J Antimicrob Agents; 2015 Jul 10; 46(1):53-9. PubMed ID: 25956844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.